Ruairi J Mackenzie
Senior Science Writer
Latest Content From Ruairi J Mackenzie
These well-known compounds have moved past decades of stigma to become well-studied therapeutics either approved or in trial to treat mental health conditions such as major depression and post-traumatic stress disorder.
On this week’s Opinionated Science, the team takes a look at the growing potential of psychedelic medicine. In this episode, we take a deep dive into four leading psychedelic compounds: psilocybin, MDMA, ketamine, and DMT.
The new study examined structural changes in the brain that might explain psilocybin’s enduring antidepressant effects.VIEW
In this special podcast collaboration with Technology Networks, we hear how cannabis edibles affect our bodies and brains and how the growing demand for edibles will see the creation of cannabis drinks and restaurants. Please bring snacks.
A new technology developed by researchers at the University of California Davis promises to fast-track the development of compounds that could exploit psychedelics’ therapeutic action without hallucinogenic side effects.VIEW
A new trial has directly compared the antidepressant effects of psilocybin with a more classical antidepressant, and found that the two are matched in their mood-altering potential.VIEW
Drug developers say that R-ketamine could potentially deliver a more targeted action with fewer side effects than its more popular chemical twin.VIEW
N,N-dimethyltryptamine (DMT) is a psychedelic compound under investigation for a range of therapeutic uses. One avenue of research is being pursued by Algernon Pharmaceuticals, who are investigating whether sub-hallucinogenic DMT doses could help to protect and repair the brain in the hours after a stroke.VIEW